Best Life Pharmanaturals LLC, et al. v. Dymatize Enterprises LLC

District Court, D. Arizona·Decided July 10, 2026·No. 2:26-cv-00235·Unknown

Opinion

WO

Best Life Pharmanaturals LLC, et al., No. CV-26-00235-PHX-KML

Plaintiffs, ORDER

v.

Dymatize Enterprises LLC,

Defendant. Plaintiffs Lisa Finder and Best Life Pharmanaturals LLC bring claims against Dymatize Enterprises LLC arising from the parties’ former nutraceutical-manufacturing relationship and an alleged 2018 assault by a Dymatize employee. Dymatize moves to dismiss all claims on a variety of bases, including untimeliness. Because plaintiffs have not plausibly alleged delayed accrual or tolling, the current claims are dismissed as untimely. The court does not reach the other grounds presented in Dymatize’s motion. I. Background Best Life Pharmanaturals LLC (“BLP”) is an Arizona nutraceutical manufacturing company founded by Lisa Finder. (Doc. 1-1 at 4, 7.) At all relevant times, Finder was BLP’s sole member and manager, and the only person with authority to make decisions on BLP’s behalf. (Doc. 1-1 at 4, 7.) In July 2017, Dymatize approached BLP about developing an L-Carnitine liquid supplement. (Doc. 1-1 at 5, 7–8.) In June 2018, they entered into an agreement (Doc. 7-3) under which BLP would manufacture and package BLP’s L-Carnitine products using Dymatize’s branding. (Doc. 1-1 at 5, 8.) The parties’ relationship deteriorated later in 2018. In October 2018, plaintiffs allege Dymatize employees began interfering with BLP’s ability to fulfill purchase orders, including by giving unauthorized instructions to BLP employees. (Doc. 1-1 at 9.) Then, in November 2018, a Dymatize employee allegedly lured Finder to his hotel room under false pretenses before physically and sexually assaulting her. (Doc. 1-1 at 9.) Finder alleges the assault caused her to develop serious health problems, including Cushing’s Syndrome, amnesia, and neurological damage. (Doc. 1-1 at 5–6, 9.) Those conditions allegedly prevented Finder from functioning in her daily life and rendered her incompetent to make informed decisions. (Doc. 1-1 at 6.) Finder underwent several surgeries and therapeutic treatments and has needed extensive caretaking from her adult daughters. (Doc. 1-1 at 11.) Plaintiffs allege Finder’s condition left BLP effectively unable to operate or manage its affairs because she was BLP’s sole member and decisionmaker, eventually resulting in the closure of the business. (Doc. 1-1 at 4, 7, 10–11.) In January 2019, Dymatize and BLP entered a “Compromise and General Release of All Claims” to resolve disputes arising from their business relationship. (Doc. 7-4 at 2.) Under the Release, BLP discharged Dymatize from all claims arising from or relating to the parties’ business relationship as of January 16, 2019, including unknown and unanticipated claims. (Doc. 7-4 at 2–3.) In exchange, Dymatize agreed to pay BLP $75,000 immediately and $1 per bottle for the next 75,000 bottles. (Doc. 7-4 at 3.) The Release laid out how the parties would divide their intellectual property in the future. (Doc. 7-4 at 3.) It also stated no promises or inducements had caused the parties to sign other than those expressly included in the agreement and the Release represented their full and final agreement on its subject matter. (Doc. 7-4 at 4–5.) Finder signed the Release on BLP’s behalf as its CEO and managing member. (Doc. 7-4 at 5–6.) Plaintiffs allege Dymatize nevertheless fraudulently induced BLP to execute the Release and stopped purchasing products from BLP immediately afterward. (Doc. 1-1 at 6, 10–11.) During the same seven-year period in which Finder allegedly was unable to manage her affairs or understand her legal rights, she actively participated in multiple lawsuits involving parties other than Dymatize.1 In March 2019, Finder filed an answer in state court, admitting and denying allegations and asserting an affirmative defense. (Docs. 8-1; 8-2.) In August 2019, acting pro se, she moved to dismiss breach-of-lease and breach-of- guaranty claims against her. (Docs. 8-3; 8-4.) In June 2023, again acting pro se, she filed an answer and counterclaim in another state-court case. (Docs. 8-5; 8-6.) A few months later, she filed an answer and counterclaim on behalf of a corporate defendant. (Doc. 8-7.) In November 2023, acting pro se, Finder filed an amended answer with counterclaims (Doc. 8-8) and submitted a sworn affidavit alongside her statement of facts (Doc. 8-9 at 6– 7). In another case, from 2023 through 2025, she filed an answer, counterclaims, oppositions to a motion to dismiss, a summary judgment motion, a motion for bifurcation, and a motion to reduce an attorneys’ fees award. (Docs. 8-10; 8-11; 8-12; 8-13; 8-14; 8- 15.) In another separate proceeding (see Docs. 8-16; 8-17; 8-18; 8-19; 8-20), Finder also opposed a request for a Rule 35 mental examination. (Doc. 8-19 at 4.) In July 2025, Finder underwent a surgery that allegedly helped her “once again become capable of managing her day-to-day affairs.” (Doc. 1-1 at 11, 16–17.) Shortly afterward, Finder discovered Dymatize had continued selling highly-concentrated L-Carnitine products after the parties’ relationship ended. (Doc. 1-1 at 11.) She alleges those products could only have been made using BLP’s proprietary production process. (Doc. 1-1 at 11.) Plaintiffs allege Dymatize primarily sold those products outside the United States, which prevented its conduct from being discovered earlier. (Doc. 1-1 at 6.) Plaintiffs filed this action in Arizona state court on December 5, 2025, and Dymatize later removed it to this court. (Doc. 1 at 2.) BLP asserts claims for breach of contract, breach of the implied covenant of good faith and fair dealing, unjust enrichment, misappropriation of trade secrets, and fraudulent inducement. (Doc. 1-1 at 12–15.) Finder asserts claims for assault and battery against Dymatize under a vicarious-liability theory. 1 Dymatize asks the court to take judicial notice of Exhibits 1–20, which consist of docket sheets and filings from state-court proceedings involving Finder. (Doc. 8 at 2–5.) The court takes notice that those documents were filed, when they were filed, and the positions Finder asserted in them, but not the truth of any disputed factual assertions they contain. See Khoja v. Orexigen Therapeutics, Inc., 899 F.3d 988, 999 (9th Cir. 2018). (Doc. 1-1 at 15–17.) II. Legal Standard “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (simplified). This is not a “probability requirement,” but a requirement that the factual allegations show “more than a sheer possibility that a defendant has acted unlawfully.” Id. A claim is facially plausible “when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. “Determining whether a complaint states a plausible claim for relief . . . [is] a context-specific task that requires the reviewing court to draw on its judicial experience and common sense.” Id. at 679. A complaint may be dismissed on limitations grounds only when untimeliness is apparent on the face of the complaint. Huynh v. Chase Manhattan Bank, 465 F.3d 992, 997 (9th Cir. 2006). “If it appears on the face of the complaint that an action may be barred by limitations, the burden is on the plaintiff to establish that the statute has been tolled.” Satamian v. Great Divide Ins. Co., 545 P.3d 918, 925 (Ariz. 2024) (simplified). When deciding a motion to dismiss, the court may consider the complaint, documents incorporated by reference, and matters subject to judicial notice. United States v. Ritchie,

Best Life Pharmanaturals LLC, et al. v. Dymatize Enterprises LLC, (D. Ariz. 2026).

Best Life Pharmanaturals LLC, et al. v. Dymatize Enterprises LLC (Best Life Pharmanaturals LLC, et al. v. Dymatize Enterprises LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Walk v. Ring
44 P.3d 990 (Arizona Supreme Court, 2002)
Allen v. Powell's International, Inc.
518 P.2d 588 (Court of Appeals of Arizona, 1974)
Florez v. Sargeant
917 P.2d 250 (Arizona Supreme Court, 1996)
Doe v. Roe
955 P.2d 951 (Arizona Supreme Court, 1998)
Cecala v. Newman
532 F. Supp. 2d 1118 (D. Arizona, 2007)
Nolde v. Frankie
964 P.2d 477 (Arizona Supreme Court, 1998)
ELM RETIREMENT CENTER, LP v. Callaway
246 P.3d 938 (Court of Appeals of Arizona, 2010)
Lien Huynh v. Chase Manhattan Bank
465 F.3d 992 (Ninth Circuit, 2006)
Kopacz v. Banner Health
425 P.3d 586 (Court of Appeals of Arizona, 2018)
Karim Khoja v. Orexigen Therapeutics, Inc.
899 F.3d 988 (Ninth Circuit, 2018)
Cavan v. Maron
182 F. Supp. 3d 954 (D. Arizona, 2016)
Deutsch v. Turner Corp.
324 F.3d 692 (Ninth Circuit, 2003)
Reddy v. Litton Industries, Inc.
912 F.2d 291 (Ninth Circuit, 1990)